Kovanecz Istvan, Rambhatla Amarnath, Ferrini Monica G, Vernet Dolores, Sanchez Sandra, Rajfer Jacob, Gonzalez-Cadavid Nestor
Urology Research Laboratory, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
BJU Int. 2008 Jan;101(2):203-10. doi: 10.1111/j.1464-410X.2007.07223.x. Epub 2007 Sep 20.
To determine whether a long-term single daily oral dose of a longer half-life phosphodiesterase-5 (PDE5) inhibitor, tadalafil, has a similar effect to that of the shorter half-life PDE5 inhibitors sildenafil and vardenafil, and can prevent the fibrosis and resultant corporal veno-occlusive dysfunction (CVOD) occurring after cavernosal nerve (CN) injury.
Male rats (10 per group) had either a sham operation, unilateral CN resection (CNR) or bilateral CNR, and were left untreated or given retrolingually 5 mg/kg per day of tadalafil. After 45 days, CVOD was assessed via cavernosometry, and the underlying corporal tissue changes were examined by immunohistochemistry and histochemistry (followed by quantitative image analysis), Western blots, and ad hoc methods.
Tadalafil treatment normalized the low response to papaverine and high drop rate in the intracavernosal pressure measured by cavernosometry after CNR compared with sham-operated rats. Tadalafil also normalized the increase in penile shaft collagen content, and the reduction in corporal smooth muscle cell (SMC) content, SMC/collagen, and replication index, and improved the lower collagen III/I ratio and the increase in apoptotic index, caused by CNR, compared with sham operation. There were no effects of tadalafil on increased transforming growth factor beta1, inducible nitric oxide synthase and xanthine oxidoreductase levels.
A long-term single daily dose of tadalafil prevented CVOD and the underlying corporal fibrosis in the rat caused by CN damage, as effectively as the previously reported continuous treatment with vardenafil or sildenafil, through a cGMP-related mechanism that appears to be independent of inducible nitric oxide synthase induction.
确定每日单次口服一剂半衰期较长的磷酸二酯酶-5(PDE5)抑制剂他达拉非,是否具有与半衰期较短的PDE5抑制剂西地那非和伐地那非类似的效果,并能否预防海绵体神经(CN)损伤后发生的纤维化及由此导致的海绵体静脉闭塞功能障碍(CVOD)。
雄性大鼠(每组10只)接受假手术、单侧CN切除(CNR)或双侧CNR,不进行治疗或经舌后给予每日5mg/kg的他达拉非。45天后,通过海绵体测压评估CVOD,并通过免疫组织化学和组织化学(随后进行定量图像分析)、蛋白质免疫印迹法及特定方法检查海绵体组织的潜在变化。
与假手术大鼠相比,他达拉非治疗使CNR后通过海绵体测压测得的对罂粟碱的低反应性及海绵体内压的高下降率恢复正常。他达拉非还使阴茎海绵体胶原含量的增加、海绵体平滑肌细胞(SMC)含量、SMC/胶原及复制指数的降低恢复正常,并改善了与假手术相比由CNR导致的较低的胶原III/I比值及凋亡指数的增加。他达拉非对转化生长因子β1、诱导型一氧化氮合酶和黄嘌呤氧化还原酶水平升高无影响。
每日单次长期服用他达拉非可预防大鼠因CN损伤引起的CVOD及潜在的海绵体纤维化,其效果与先前报道的连续服用伐地那非或西地那非相同,通过一种似乎独立于诱导型一氧化氮合酶诱导的cGMP相关机制发挥作用。